Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.46 |
| ▸ | TERT | O14746 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 9/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8368761 | 0.89 | TERT (0.44) | TBXAS1TERTTAAR1HTR1ACYP1A2 | |
| SCHEMBL31617008 | 0.88 | TERT (0.43) | TBXAS1TERTTAAR1HTR1ANAMPT | |
| SCHEMBL5148222 | 0.86 | TERT (0.42) | TBXAS1TERTTAAR1HTR1ACYP1A2 | |
| SCHEMBL8220822 | 0.85 | TBXAS1 (0.46) | TBXAS1TERTTAAR1HTR1ACYP1A2 | |
| SCHEMBL16411032 | 0.84 | TBXAS1 (0.37) | TBXAS1TERTTAAR1HTR1ACYP1A2 | |
| SCHEMBL31616933 | 0.84 | TERT (0.43) | TBXAS1TERTTAAR1HTR1ACYP1A2 | |
| SCHEMBL1899700 | 0.81 | TBXAS1 (0.49) | TBXAS1TERTTAAR1HTR1ACYP1A2 | |
| SCHEMBL593689 | 0.79 | CYP3A4 (0.46) | TBXAS1TERTTAAR1HTR1ACYP1A2 | |
| SCHEMBL81566 | 0.79 | — | — | |
| SCHEMBL3431746 | 0.78 | TBXAS1 (0.66) | TBXAS1TERTTAAR1HTR1AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034600-A1 | ONIUM SALT COMPOSITIONS, METHODS FOR PRODUCING CELLULOSE HYDROLYSATES, ALCOHOLS AND/OR ORGANIC ACIDS IN THE PRESENCE OF ONIUM SALT COMPOSITIONS | KOEI CHEMICAL COMPANY, LIMITED (JP) | 2025-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034600-A1 | ONIUM SALT COMPOSITIONS, METHODS FOR PRODUCING CELLULOSE HYDROLYSATES, ALCOHOLS AND/OR ORGANIC ACIDS IN THE PRESENCE OF ONIUM SALT COMPOSITIONS | ADH5, ADH1C, AMY1A | TBXAS1 3496/4885TERT 1487/4885TAAR1 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.